EDWARDS LIFESCIENCES CORP's ticker is EW and the CUSIP is 28176E108. A total of 1,176 filers reported holding EDWARDS LIFESCIENCES CORP in Q2 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
About EDWARDS LIFESCIENCES CORP
Edwards Lifesciences Corp is a medical technology company that specializes in heart valves and hemodynamic monitoring. The company was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences Corp is a leader in the development of innovative medical devices that improve patient outcomes and quality of life.
One of the company's most significant products is the SAPIEN transcatheter heart valve, which is used to treat patients with aortic stenosis. This condition occurs when the aortic valve in the heart narrows, making it difficult for blood to flow through. The SAPIEN valve is inserted through a small incision in the leg and guided to the heart, where it is expanded to replace the damaged valve. This minimally invasive procedure has revolutionized the treatment of aortic stenosis and has helped thousands of patients worldwide.
Edwards Lifesciences Corp has also developed a range of hemodynamic monitoring devices that help clinicians manage critically ill patients. These devices provide real-time information about a patient's cardiovascular status, allowing clinicians to make informed decisions about treatment.
The company has a strong commitment to research and development, with a significant portion of its revenue invested in this area. This investment has led to the development of new products and technologies that have improved patient outcomes and expanded the company's market share.
In conclusion, Edwards Lifesciences Corp is a leading medical technology company that has made significant contributions to the field of cardiovascular medicine. Its innovative products and commitment to research and development have helped improve the lives of patients worldwide.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,602,432 | -3.9% | 28,174 | -0.5% | 0.05% | -3.6% |
| Q1 2024 | $2,706,641 | +25.1% | 28,324 | -0.2% | 0.06% | +14.6% |
| Q4 2023 | $2,163,517 | +10.1% | 28,374 | 0.0% | 0.05% | 0.0% |
| Q3 2023 | $1,965,751 | -27.0% | 28,374 | -0.5% | 0.05% | -23.8% |
| Q2 2023 | $2,691,141 | +14.4% | 28,529 | +0.3% | 0.06% | +6.8% |
| Q1 2023 | $2,353,255 | +110537.3% | 28,445 | -0.2% | 0.06% | +7.3% |
| Q4 2022 | $2,127 | -99.9% | 28,506 | 0.0% | 0.06% | -40.2% |
| Q3 2022 | $2,355,000 | -14.4% | 28,506 | -1.4% | 0.09% | -9.8% |
| Q2 2022 | $2,750,000 | -19.4% | 28,915 | -0.2% | 0.10% | -4.7% |
| Q1 2022 | $3,411,000 | -8.9% | 28,976 | +0.3% | 0.11% | -1.8% |
| Q4 2021 | $3,743,000 | +12.9% | 28,894 | -1.3% | 0.11% | +1.9% |
| Q3 2021 | $3,316,000 | +9.3% | 29,287 | 0.0% | 0.11% | +8.1% |
| Q2 2021 | $3,033,000 | +23.7% | 29,287 | -0.0% | 0.10% | +16.5% |
| Q1 2021 | $2,451,000 | -8.3% | 29,300 | 0.0% | 0.08% | +30.8% |
| Q4 2020 | $2,673,000 | +10.9% | 29,300 | -3.0% | 0.06% | -1.5% |
| Q3 2020 | $2,411,000 | +15.5% | 30,210 | 0.0% | 0.07% | +3.1% |
| Q2 2020 | $2,088,000 | +8.9% | 30,210 | +197.3% | 0.06% | -11.1% |
| Q1 2020 | $1,917,000 | -19.1% | 10,162 | 0.0% | 0.07% | +2.9% |
| Q4 2019 | $2,371,000 | +6.0% | 10,162 | -0.1% | 0.07% | -1.4% |
| Q3 2019 | $2,237,000 | +19.1% | 10,172 | 0.0% | 0.07% | +14.5% |
| Q2 2019 | $1,879,000 | -5.5% | 10,172 | -2.1% | 0.06% | -8.8% |
| Q1 2019 | $1,988,000 | +24.9% | 10,391 | 0.0% | 0.07% | +11.5% |
| Q4 2018 | $1,592,000 | -12.0% | 10,391 | 0.0% | 0.06% | +3.4% |
| Q3 2018 | $1,809,000 | +18.2% | 10,391 | -1.1% | 0.06% | +11.3% |
| Q2 2018 | $1,530,000 | +3.9% | 10,511 | -0.5% | 0.05% | +1.9% |
| Q1 2018 | $1,473,000 | +26.1% | 10,561 | +1.9% | 0.05% | +30.0% |
| Q4 2017 | $1,168,000 | +4.7% | 10,359 | +1.4% | 0.04% | 0.0% |
| Q3 2017 | $1,116,000 | -3.5% | 10,214 | +4.5% | 0.04% | -7.0% |
| Q2 2017 | $1,156,000 | +25.7% | 9,776 | 0.0% | 0.04% | +22.9% |
| Q1 2017 | $920,000 | +0.4% | 9,776 | 0.0% | 0.04% | -5.4% |
| Q4 2016 | $916,000 | -21.8% | 9,776 | +0.6% | 0.04% | -26.0% |
| Q3 2016 | $1,172,000 | +20.9% | 9,720 | 0.0% | 0.05% | +22.0% |
| Q2 2016 | $969,000 | +8.5% | 9,720 | -4.0% | 0.04% | +7.9% |
| Q1 2016 | $893,000 | +11.8% | 10,120 | 0.0% | 0.04% | +15.2% |
| Q4 2015 | $799,000 | +11.1% | 10,120 | +100.0% | 0.03% | +3.1% |
| Q3 2015 | $719,000 | -0.3% | 5,060 | 0.0% | 0.03% | +6.7% |
| Q2 2015 | $721,000 | 0.0% | 5,060 | 0.0% | 0.03% | 0.0% |
| Q1 2015 | $721,000 | +0.4% | 5,060 | -10.3% | 0.03% | +3.4% |
| Q4 2014 | $718,000 | +38.9% | 5,640 | +11.5% | 0.03% | +31.8% |
| Q3 2014 | $517,000 | +20.5% | 5,060 | +1.2% | 0.02% | +22.2% |
| Q2 2014 | $429,000 | +12.9% | 5,000 | -2.3% | 0.02% | +5.9% |
| Q1 2014 | $380,000 | +12.8% | 5,120 | 0.0% | 0.02% | +13.3% |
| Q4 2013 | $337,000 | -5.6% | 5,120 | 0.0% | 0.02% | -16.7% |
| Q3 2013 | $357,000 | +3.8% | 5,120 | 0.0% | 0.02% | -30.8% |
| Q2 2013 | $344,000 | – | 5,120 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 147,396 | $19,095,000 | 7.52% |
| Triodos Investment Management BV | 409,800 | $53,090,000 | 6.94% |
| Wedgewood Partners | 353,149 | $45,749,000 | 6.07% |
| Ownership Capital B.V. | 4,074,240 | $527,818,000 | 5.72% |
| MARVIN & PALMER ASSOCIATES INC | 91,933 | $11,910,000 | 5.10% |
| CAPITAL COUNSEL LLC/NY | 836,197 | $108,329,000 | 4.59% |
| TSFG, LLC | 84,591 | $10,959,000 | 3.81% |
| STONE RUN CAPITAL, LLC | 89,225 | $11,559,000 | 3.73% |
| CIM, LLC | 175,972 | $19,267,000 | 3.60% |
| Lowell Blake & Associates Inc. | 67,880 | $8,794,000 | 3.45% |